Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by SAB Biotherapeutics, Inc. SAb Biotherapeutics Rebrands as SAB BIO June 20, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions June 18, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Announces Departure of Chief Financial Officer May 30, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics May 21, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates May 20, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors May 06, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Provides SAB-142 Trial Update April 16, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics to Present at INNODIA Annual Meeting April 08, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference April 04, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment March 25, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics to Present at the BIO CEO & Investor Conference February 23, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 08, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Announces Executive Leadership Change February 02, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement January 23, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split January 02, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes November 29, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors November 20, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes November 14, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates November 14, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference November 09, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer October 24, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes October 19, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors October 05, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes October 02, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results August 21, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023 June 21, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention May 30, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations May 19, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results May 16, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies May 12, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Tickers SABS SABSW Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.